CVRS CORINDUS VASCULAR ROBOTICS

Corindus Vascular Robotics Appoints Jeff Lemaster Chief Commercial Officer

WALTHAM, Mass.--(BUSINESS WIRE)--

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, today announced the appointment of Jeff Lemaster as Chief Commercial Officer.

Mr. Lemaster brings 20 years of commercial sales and marketing experience in the cardiovascular medical device industry to Corindus and has extensive global new product launch experience in the areas of interventional cardiology and peripheral. He most recently served as Global Vice President, Marketing of C.R. Bard, Inc. [NYSE: BCR], a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies. He has a proven track record of commercial success having held senior sales and marketing leadership positions at C.R. Bard, ACIST Medical Systems and Boston Scientific Corporation (NYSE: BSX).

As Chief Commercial Officer at Corindus, Mr. Lemaster will lead and execute revenue and commercial strategy to drive growth and market adoption globally.

"I am delighted to welcome Jeff to Corindus, and we look forward to his future contributions. His extensive commercial experience, particularly in the interventional and peripheral arena, will enable us to build and sustain strong robotic programs that benefit our customers and their patients," said Corindus CEO, Mark J. Toland.

"I look forward to working with the Corindus team and the broader interventional community to build robotic programs that transform the way we treat patients while protecting cath lab teams," said Mr. Lemaster.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to complex, radial, coronary and peripheral procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

EN
20/10/2016

Underlying

CVRSCORINDUS VASCULAR ROBOTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CORINDUS VASCULAR ROBOTICS

 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus Vascular Robotics, Inc. Stockholders Approve Acquisition by S...

WALTHAM, Mass.--(BUSINESS WIRE)-- At a special meeting today, stockholders of Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS) approved the adoption of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 7, 2019, by and among Siemens Medical Solutions USA, Inc. (“SMS USA”), Corpus Merger Inc. (“Merger Sub”) and Corindus. Subject to the terms and conditions of the Merger Agreement, Merger Sub, a wholly owned subsidiary of SMS USA, will be merged with and into Corindus, with Corindus surviving the merger as a wholly owned subsidiary o...

October 25, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus to Showcase CorPath® GRX System at Transcatheter Cardiovascu...

WALTHAM, Mass.,--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it will showcase the capabilities of the CorPath® GRX system at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 Conference, to be held September 25-29 in San Francisco, California. CorPath GRX is the only U.S. Food and Drug Administration (“FDA”) cleared and CE-marked medical device for robotic-assisted vascular interventions. At Corindus’ booth 1327, attendees will be able to gain hands-on experience with CorPath GRX in an advanc...

September 18, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

First-in-Human Telerobotic Coronary Intervention Procedures Published ...

WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has published the results from the , the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catheterization lab using Corindus’ CorPath technology platform. The paper, titled Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience, d...

September 3, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus Reports Second Quarter 2019 Results

WALTHAM, Mass.--(BUSINESS WIRE)-- , Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2019. Corindus also announced today that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggr...

August 8, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus Vascular Robotics Announces Definitive Agreement to Be Acquir...

WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion. “We are pleased to ...

August 8, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch